ASN007 is indicated for treating chronic hepatitis B in adults and adolescents. Current commercial formulations require once-daily dosing, due to the long-term treatment, it is inconvenient and the missing doses may lead to disease exacerbation. To enhance the drug compliance and treatment outcome, Auson has developed an innovative drug product that is administered once weekly.